While the seemingly endless M&A process among generic drug companies means that the acquisition of Par Pharmaceuticals (PRX)
isn't a complete surprise, it's an interesting deal all the same. Not
only does this deal point to the cost of not having a truly global
business, but it also seems to speak to the extent to which this sector
could see pipeline-driven valuation worries in the coming years.
Please click here for more:
TPG's Bid For Par Reflects More Difficult Generic Environment
No comments:
Post a Comment